A fusion protein involving the DNA-binding domain of a transcription factor, such as DDIT3 or ERG, and the LC domain of FUS can redirect RNA Pol II activity sufficient to drive Ewing and other sarcomas (1, 41). Here, ERG is linked to sarcoma.